Prednisone and B-cell lymphoma refractory - a phase IV clinical study of FDA data

Summary:

B-cell lymphoma refractory is reported as a side effect among people who take Prednisone (prednisone), especially for people who are male, 50-59 old, also take Cyclophosphamide, and have Burkitt lymphoma.

The phase IV clinical study analyzes which people have B-cell lymphoma refractory when taking Prednisone. It is created by eHealthMe based on reports of 628,814 people who have side effects when taking Prednisone from the FDA, and is updated regularly.

What is Prednisone?

Prednisone has active ingredients of prednisone. It is often used in rheumatoid arthritis. eHealthMe is studying from 636,827 Prednisone users. Check the latest studies of Prednisone.

What is B-cell lymphoma refractory?

B-cell lymphoma refractory (blood cancer affecting b cells-relapsed) is found to be associated with 11 drugs and 4 conditions by eHealthMe. Check the latest studies of B-cell lymphoma refractory.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 18, 2026

628,814 people reported to have side effects when taking Prednisone.
Among them, 22 people (0.0%) have B-cell lymphoma refractory.

$Could Prednisone cause B-cell lymphoma refractory?$

Among these 22 people:

What is the gender of people who have B-cell lymphoma refractory when taking Prednisone? *

female: 25 %
male: 75 %

What is the age of people who have B-cell lymphoma refractory when taking Prednisone? *

What are other drugs people take besides Prednisone? *

Cyclophosphamide: 14 people, 63.64%
Doxorubicin Hydrochloride: 12 people, 54.55%
Cytarabine: 12 people, 54.55%
Dexamethasone: 10 people, 45.45%
Etoposide: 9 people, 40.91%
Vincristine Sulfate: 9 people, 40.91%
Ifosfamide: 8 people, 36.36%
Cisplatin: 8 people, 36.36%
Carboplatin: 8 people, 36.36%
Mirtazapine: 7 people, 31.82%

What are other side effects people have besides B-cell lymphoma refractory? *

Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 11 people, 50.00%
B-Cell Lymphoma Recurrent (blood cancer affecting b cells-recurrent): 8 people, 36.36%
Metastases To Spleen (cancer spreads to spleen): 7 people, 31.82%
Death: 7 people, 31.82%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 7 people, 31.82%
Metastases To Lung (cancer spreads to lung): 7 people, 31.82%
Headache (pain in head): 7 people, 31.82%
Disease Progression: 6 people, 27.27%
Diffuse Large B-Cell Lymphoma Recurrent (recurrent cancer of b cells, a type of white blood cell): 6 people, 27.27%
Drug Ineffective: 4 people, 18.18%

What are the existing conditions these people have? *

Burkitt Lymphoma (cancer of the lymphatic system): 5 people, 22.73%
Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 4 people, 18.18%
B-Cell Lymphoma Stage Ii (blood cancer affecting b cells stage ii): 2 people, 9.09%
B-Cell Lymphoma Stage Iv (blood cancer affecting b cells stage iv): 1 person, 4.55%
B-Cell Lymphoma Stage Iii (blood cancer affecting b cells stage iii): 1 person, 4.55%
B-Cell Lymphoma Recurrent (blood cancer affecting b cells-recurrent): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Prednisone and have B-cell lymphoma refractory?

- Check whether B-cell lymphoma refractory is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Prednisone:

Prednisone (636,827 reports)

Browse all side effects of Prednisone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with B-cell lymphoma refractory:

B-cell lymphoma refractory (11 drugs)

Browse all the conditions that are associated with B-cell lymphoma refractory:

B-cell lymphoma refractory (4 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on prednisone (the active ingredients of Prednisone) and Prednisone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.